secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greater Cannabis Company, Inc. (GCAN)
CIK:        0001695473
Form:       8-K
Filed at:   2021-08-19T23:59:59+00:00
Accession:  0001493152-21-020666
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GCAN signs licensing/research deal with Shaare Zedek for cannabinoid therapy targeting neuropsychiatric disorders
--------------------------------------------------------------------------------

- Licensing covers novel cannabinoid therapeutic for autism, schizophrenia, Parkinson's, Alzheimer's, and other neuropsychiatric disorders.
- Joint R&D agreement with Shaare Zedek Scientific, technology transfer arm of Jerusalem's Shaare Zedek Medical Center.
- Dr. Adi Aran, SZMC pediatric neurology director and cannabis research pioneer, will lead continued clinical program.
- Director David Tavor resigned effective August 19, 2021.
- No financial terms of the agreements were disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1695473/000149315221020666/0001493152-21-020666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1695473/000149315221020666/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-020666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer